Adverse drug events of immune checkpoint inhibitors - a retrospective, descriptive real-world data analysis
Nearly half of the patients experienced ≥ 1 irAEs, of which one-third severe. Females experienced more irAEs than males, above all due to a higher incidence of grade 1 irAEs. Only about half of the irAEs were reported as coded diagnosis. Further prospective studies on irAEs are warranted using structured documentation.
Authors
- Dirk Lehnick (ORCID: https://orcid.org/0000-0003-1836-2811)
- Balthasar L. Hug (ORCID: https://orcid.org/0000-0003-4235-1995)
- Chloé Sieber (ORCID: https://orcid.org/0000-0002-6642-5082)
- Lauris Annatha Mariam Auch (ORCID: https://orcid.org/0009-0008-0663-1408)
Institutions
- University of Lucerne (CH)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1186/s12885-025-14733-5
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18